About Gemin X Pharmaceuticals
Gemin X Pharmaceuticals is a Healthcare company based in Malvern (United States) founded in 1998, and was acquired by Cephalon in March 2011. Cancer therapeutics and drugs are discovered, developed, and manufactured. Gemin X Pharmaceuticals has raised $62 million across 4 funding rounds from investors including Cephalon, BDC and Ontario Teachers' Pension Plan. Its focus areas include Life Sciences, Oncology, Drugs and Pan Cancer. Its legal entity is GEMIN X PHARMACEUTICALS US, INC. Its competitors include TScan Therapeutics, GigaGen and Shattuck Labs; 3 of its 3 listed competitors have raised funding.
Company details
Gemin X Pharmaceuticals was founded in 1998 in Malvern, United States, with a focus on the oncology sector. Cancer therapeutics and drugs are discovered, developed, and manufactured by the company, including GX15-070, a small molecule that reinitiates apoptosis, and GMX1777, an inhibitor of NAD synthesis. Other oncology products are also provided. Operations centered on these activities until the company was acquired by Cephalon in April 2011.
- Headquarters Malvern, United States
- Stage Acquired
- SectorsHealthcare
- Website geminx.com
- Social LinkedIn
- Acquired by Cephalon (Mar 2011)
- Legal Name Gemin X Pharmaceuticals Us, Inc.
Funding Insights of Gemin X Pharmaceuticals
Gemin X Pharmaceuticals has successfully raised a total of $62M across 4 strategic funding rounds. The most recent funding activity was a Series E round of $8 million completed in August 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $62M
- Total Rounds 4
- Last Round Series E — $8M
- First Round $38M
(Jul 2008)
- Investors Count 13
All 4 funding rounds of Gemin X Pharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2010 | $8M | Series E | – | – | |
| Apr 2010 | $16M | Series D | – | Caxton Advantage, Sanderling Ventures | – |
| Jun 2009 | $9.26M | Debt – Conventional | – | – | – |
| Jul 2008 | $38M | Series C | – | – |
14 investors in total: 14 institutional.
Investors in Gemin X Pharmaceuticals
Gemin X Pharmaceuticals has secured backing from 14 investors, including venture fund and institutional investors. Prominent investors backing the company include Cephalon, BDC and Ontario Teachers' Pension Plan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| caxtonadvantage.com | ||||
Biomedical investment financing and active management services. | sanderling.com | |||
Venture capital firm | vpcp.com | Santa Barbara, United States | ||
| proquestvc.com | ||||
Biotechnology investments are targeted by the venture capital firm. | merlinbiomed.com | New York, United States | ||
Late-stage life sciences investments are managed via VC and PE. | hbmpartners.com | Zug, Switzerland | ||
Stage-agnostic sector-agnostic VC firm investing in Canada and the US | growthworks.ca | Vancouver, Canada | ||
Venture debt and equity financing are provided across US sectors. | 2002 | pinnacleventures.com | Palo Alto, United States | |
Pension funds focused on multiple sectors | 1990 | otpp.com | Toronto, Canada | |
| sblifescience.com |
Investor details for Gemin X Pharmaceuticals
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Gemin X Pharmaceuticals
4 dated milestones of Gemin X Pharmaceuticals across 13 years, from founding to its latest funding, stage changes and deals.
- Founded Gemin X Pharmaceuticals is founded.
- Funding First funding round of $38.0M.
- Funding Latest funding round, Series E, of $8.0M.
- Exit Acquired by Cephalon.
Competitors of Gemin X Pharmaceuticals
Gemin X Pharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include TScan Therapeutics, GigaGen and Shattuck Labs.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| tscan.com | 1995 | Boston, United States | $158.3M | 154 | T cell-based treatments for immunological and oncological disorders are developed. | |
| gigagen.com | 2011 | San Francisco, United States | $36.13M | 36 | T-cell and antibody-based therapeutics are developed via single-cell sequencing platforms. | |
| shattucklabs.com | 2016 | Austin, United States | $165.4M | 89 | An immunotherapy platform for oncology and other diseases is developed. |
Detailed competitors of Gemin X Pharmaceuticals
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as Gemin X Pharmaceuticals (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Gemin X Pharmaceuticals
Gemin X Pharmaceuticals was founded in 1998 and raised its 1st funding round 10 years after it was founded.
Gemin X Pharmaceuticals is headquartered in Malvern, United States. It is registered at Malvern, Pennsylvania, United States.
Gemin X Pharmaceuticals is a funded company, having raised a total of $62M across 4 funding rounds to date. The company's 1st funding round was a Series C of $38M, raised on Jul 2008.
Gemin X Pharmaceuticals was founded in 1998 in Malvern, United States, with a focus on the oncology sector. Cancer therapeutics and drugs are discovered, developed, and manufactured by the company, including GX15-070, a small molecule that reinitiates apoptosis, and GMX1777, an inhibitor of NAD synthesis. Other oncology products are also provided. Operations centered on these activities until the company was acquired by Cephalon in April 2011.
Gemin X Pharmaceuticals's top competitors include GigaGen, Shattuck Labs and TScan Therapeutics.
Gemin X Pharmaceuticals has 14 investors. Key investors include Cephalon, BDC, Ontario Teachers' Pension Plan, Pinnacle Ventures, and Caxton Advantage.
Gemin X Pharmaceuticals operates through Gemin X Pharmaceuticals Us, Inc..
Yes. Gemin X Pharmaceuticals was acquired by Cephalon in March 2011.